What was the NPC trial that started the selenium-cancer interest?

The Nutritional Prevention of Cancer trial published by Clark and colleagues in JAMA 1996. A randomised controlled trial of 1,312 American adults with prior non-melanoma skin cancer, supplemented with 200 mcg selenium daily or placebo. Primary endpoint was new non-melanoma skin cancer — no benefit. But the secondary analysis showed apparent reductions in prostate, lung, and colorectal cancer incidence in the selenium group. That secondary signal generated decades of follow-up trials. The signal did not replicate at larger scale.

What did the SELECT trial actually find?

The Selenium and Vitamin E Cancer Prevention Trial, published in JAMA 2009 (and follow-up updates through 2014). 35,533 men randomised to 200 mcg selenium, 400 IU vitamin E, both, or placebo for primary prevention of prostate cancer. No reduction in prostate cancer in either active arm. A statistically significant increase in prostate cancer in the vitamin E arm, and a statistically significant increase in type 2 diabetes incidence in the selenium arm (though this finding has been debated). The trial was stopped early.

Should I take selenium if I have Hashimoto's or thyroid disease?

Mixed evidence. Some small trials show that selenium 200 mcg/day reduces thyroid peroxidase antibody titres in Hashimoto's. Whether this translates to clinical outcomes (reduced progression to hypothyroidism, reduced symptoms) is less clear. AU endocrinology practice doesn't routinely recommend selenium for Hashimoto's. The Endocrine Society of Australia and the Australasian Thyroid Foundation include the evidence as 'limited' rather than endorsed. Worth discussing with a treating endocrinologist if relevant.

Is selenium toxic at high doses?

Yes. Selenosis develops at sustained intake above approximately 400 mcg/day, with hair and nail brittleness, garlic-smelling breath, peripheral neuropathy, and GI symptoms. The NHMRC Upper Level of Intake for adults is 400 mcg/day from all sources combined. A Brazil nut contains 50–90 mcg selenium per nut, with substantial variability — daily handfuls can exceed the UL.

Are Australians selenium-deficient?

Generally no. Most Australian soils have moderate selenium content; dietary diversity provides adequate intake for most adults. Specific at-risk groups: people on long-term parenteral nutrition, severe inflammatory bowel disease, hospitalised malnourished patients, and prolonged restrictive eating patterns. Population-wide selenium supplementation is not recommended by NHMRC, RACGP, or Cancer Council Australia.

Selenium and cancer: what the SELECT trial and others actually showed

The arc of the selenium story

Few supplement narratives have travelled further from initial promise to current consensus than selenium and cancer prevention.

In 1996, the Nutritional Prevention of Cancer (NPC) trial by Clark and colleagues — 1,312 American adults with prior non-melanoma skin cancer, supplemented with 200 mcg selenium daily — found no effect on the primary endpoint (new non-melanoma skin cancer) but, in secondary analysis, apparent reductions in prostate, lung, and colorectal cancer incidence. The signal was unexpected and the paper triggered substantial follow-up research.

In 2009, the SELECT trial (Selenium and Vitamin E Cancer Prevention Trial) reported on 35,533 men randomised to selenium, vitamin E, both, or placebo for primary prevention of prostate cancer. After approximately 5.5 years of follow-up, no reduction in prostate cancer in either active arm. The vitamin E arm showed a statistically significant increase in prostate cancer; the selenium arm showed a statistically significant increase in type 2 diabetes incidence.

The 2018 Cochrane systematic review by Vinceti et al. pooled 83 studies and concluded there was no convincing evidence that selenium supplementation reduces cancer risk in well-nourished populations, and possible signals of harm in some endpoints.

That is where the consensus sits. The promising 1996 signal didn’t survive larger, more rigorous testing.

A. Core clinical — what selenium does, and what the AU evidence supports

Selenium is an essential trace element. It is the cofactor for ~25 mammalian selenoproteins, including glutathione peroxidases (antioxidant defence) and the iodothyronine deiodinases (thyroid hormone metabolism). NHMRC Nutrient Reference Values:

Group	Adequate Intake
Adult women	60 mcg/day
Adult men	70 mcg/day
Pregnancy	65 mcg/day
Lactation	75 mcg/day
Adult Upper Level	400 mcg/day from all sources

Severe selenium deficiency is rare in Australia. Most soils have adequate selenium content; dietary diversity supplies the rest. Specific groups at risk: long-term parenteral nutrition, severe inflammatory bowel disease (high stoma output, fat malabsorption), prolonged restrictive eating, and certain populations in selenium-poor soil regions (parts of China, Russia — not relevant to AU).

Clinical contexts where AU primary tier supports selenium replacement:

Documented deficiency (low serum selenium with consistent clinical picture)
Long-term parenteral nutrition (per AU clinical-nutrition standards)
Specific genetic conditions affecting selenium metabolism (rare)

Clinical contexts where AU primary tier does NOT support routine selenium supplementation:

Cancer prevention in non-deficient adults
Cardiovascular prevention
Anti-ageing or general wellness
Cognitive decline prevention
COVID-19 prevention or treatment (despite widespread claims during the pandemic)

The Cancer Council Australia does not recommend selenium supplementation for cancer prevention. Choosing Wisely Australia lists routine multivitamin / mineral supplementation in non-deficient adults as a low-value practice.

B. Evidence appraisal — the contested zones

Hashimoto’s thyroiditis. Several small trials have shown that selenium 200 mcg/day reduces thyroid peroxidase antibody titres in Hashimoto’s. Whether this translates to clinical outcomes — slower progression to hypothyroidism, reduced symptoms — is less established. The Endocrine Society of Australia includes this as ‘limited evidence’. Some Australian endocrinologists trial it; many do not. Worth discussing with a treating endocrinologist if relevant; not a routine GP-led prescription.

Graves’ ophthalmopathy. A 2011 NEJM trial showed selenium 100 mcg twice daily for 6 months reduced eye-disease progression in mild Graves’ orbitopathy. AU endocrinology practice may use it in this specific context, in coordination with thyroid and ophthalmic care.

Fertility — male. Some trials show selenium + vitamin E may improve semen quality parameters in subfertile men. Effect sizes are modest; AU reproductive medicine practice varies. Not a substitute for evaluation of underlying causes.

HIV / HCV. Some trials of selenium in HIV-positive populations showed reduced disease progression. AU infectious-disease practice doesn’t routinely supplement, but the evidence is more supportive than in general adult populations.

COVID-19. Despite widespread claims during the pandemic, AU primary tier (RACGP, Department of Health, NHMRC) does not support selenium supplementation for COVID-19 prevention or treatment.

C. Selenium toxicity — when supplementation harms

Selenosis develops at sustained intake above approximately 400 mcg/day (the NHMRC Upper Level). Symptoms:

Hair and nail brittleness (often the earliest)
Garlic-smelling breath
Peripheral sensory neuropathy
Gastrointestinal symptoms (nausea, diarrhoea)
Fatigue
Skin rash and dermatitis

The 2009 SELECT trial’s diabetes signal in the selenium arm has been debated but represents one documented adverse outcome from sustained high-dose supplementation in adults.

A practical Australian-specific point: Brazil nuts. Single Brazil nuts contain 50–90 mcg selenium each, with substantial variability between nuts (some have 200+ mcg). Daily consumption of a handful of Brazil nuts can exceed the NHMRC UL. The popular advice “eat 1 Brazil nut a day for selenium” is reasonable; “eat 5–10 Brazil nuts a day for thyroid health” is not.

D. Practical guidance

Don’t supplement for cancer prevention. The trial evidence is consistent that this doesn’t work in well-nourished adults.

Don’t supplement routinely in non-deficient adults — wellness or “antioxidant support” framing is not supported.

Test only when clinically indicated. Suspected deficiency in malabsorption, prolonged restrictive eating, or symptoms aligned with selenoprotein deficiency.

If you have Hashimoto’s and are considering selenium, discuss with a treating endocrinologist. The trial evidence supports a discussion, not a default.

Audit total daily intake if you’re already on multiple supplements. Multivitamins, immune-support formulations, and prostate-support supplements often contain 100–200 mcg selenium each. Stacked, plus dietary intake, plus Brazil nuts — you can exceed the UL.

Food-first sources in Australia: Brazil nuts (variable, high), tuna and salmon, eggs, beef, chicken, wholegrain breads, mushrooms, sunflower seeds. A varied AU diet typically supplies adequate selenium.

(MBS / PBS items verified 2026-05-17 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current. Note that supplemental selenium is not PBS-listed.)

What this article is and is not

This is general health information drawn from NHMRC Nutrient Reference Values, Cancer Council Australia diet-and-cancer guidance, AU endocrinology references, and the major peer-reviewed selenium-cancer trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about selenium testing or supplementation are made with your own GP or treating specialist.

For Australian consumer-friendly sources: HealthDirect, Cancer Council Australia.